Urology Medical News about Castration

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathways
Maturitas, 10/16/09

Pal SK et al. – A recent phase I/II trial of MDV3100 in castrate–resistant prostate cancer demonstrated tolerability of the agent with activity at the lowest dose level. On the basis of these compelling data, both abiraterone and MDV3100 will be examined in the phase III setting.

<< Previous
The Role of Cytokine Expression in Different Subgroups of...

Next >>
Medicaid pay could be cut again when stimulus money runs out

Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer
Cancer Research, 10/06/09 Relevance Score: 83%

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
Cancer Immunology, Immunotherapy, 11/12/09 Relevance Score: 82%

Parasitic castration: the evolution and ecology of body snatchers
Trends in Parasitology, 10/07/09 Relevance Score: 82%

Seminoma necrosis by testicular torsion
Der Urologe, 10/30/09 Relevance Score: 80%

Palliative systemic therapy of castration-resistant prostate cancer
Der Urologe, 10/29/09 Relevance Score: 80%